Wed, Feb. 18, 10:38 AM
- Long-suffering bulls are finally getting some positive action from Amarin (AMRN +13.6%) after SunTrust Bank upgrades it to Buy from Neutral with a $6 price target.
- The stock sank as low as $0.78 (November 11) which was 96% below its late May 2011 peak of $19.87. Shares cratered in October 2013 after the FDA withdrew its Special Protocol Assessment (SPA) for Vascepa and a negative Ad Comm vote against an expanded label.
- Previously: Panel votes against label expansion for Amarin's Vascepa (Oct. 16, 2013)
- Previously: Amarin tumbles as FDA pulls SPA (Oct. 29, 2013)
Wed, Feb. 18, 9:15 AM
Dec. 15, 2014, 12:36 PM
- Added to the Nasdaq Biotechnology Index, effective Dec. 22: AAVL, AERI, AKBA, ALDR, ALIM, AMPH, ANIP, ASPX, CARA, CGEN, CLDN, CNCE, ENTA, FLML, FMI, FOLD, FPRX, GWPH, HPTX, ICPT, INO, INSM, KITE, KPTI, MGNX, OPHT, PCYC, PETX, POZN, PTX, QLTI, RARE, RCPT, RDUS, RLYP, RTRX, RVNC, SAGE, TBPH, TTPH, VSAR, XLRN, ZFGN, ZSPH.
- Deleted: AMRN, AUXL, CRIS, EXPR, ICEL, ONTX, RIGL, ZGNX.
- Source: Press Release
Nov. 18, 2014, 12:49 PM
Nov. 18, 2014, 11:41 AM
- Amarin (AMRN +22.4%) is up again today on a 50% increase in volume as money flows into the stock in response to a presentation of new data and analyses from the Marine and Anchor Phase 3 Vascepa (icosapent ethyl) trials. Shares are now up 54% from the low of $0.78 on November 11.
- In a poster session at this week's American Heart Association meeting in Chicago, investigators, Dr. Christie M. Ballantyne presented data that showed the use of Vascepa significantly reduced remnant-like particle cholesterol (RLP-C) levels in patients with triglyceride levels between 200 mg/dL and 500 mg/dL compared to placebo, including patients on statin therapy.
- Vascepa reduced median RLP-C levels 29.8% (p=0.0041) in the Marine study and 25.8% (p=0.0001) in Anchor, both compared to placebo.
- RLP-C is an emerging risk factor for cardiovascular disease. It represents the cholesterol content of a subset of triglyceride-rich lipoproteins called remnants.
- Even with the recent rally, shares are down over 80% from October 2013.
Nov. 6, 2014, 4:03 PM
Nov. 5, 2014, 5:35 PM
- ABCO, ACET, AEL, AGO, AIRM, AL, ALIM, AMRN, ANAC, ANET, APEI, ARC, AUQ, BBRG, BCEI, BEBE, BNFT, BPZ, BRKR, BRS, CFN, CLVS, CPST, CSC, CVT, DAR, DIOD, DIS, DVA, DXCM, EAC, EBS, ECOM, ECPG, ED, EGOV, ELON, ENOC, ENV, EVC, EZPW, FF, FI, FICO, FIVN, FNGN, FSLR, FTEK, FWM, FXCM, GST, GXP, HCI, HGR, HNSN, HPTX, HTGC, IGT, INFI, JJSF, KING, KOG, KTOS, LGF, LNT, LOCO, MATX, MDRX, MDVN, MITK, MM, MNST, MNTX, MRC, MSCC, MTD, NES, NFG, NKTR, NOG, NU, NVDA, NVDQ, OLED, ONTY, PCTY, PFMT, PRO, PSEC, PSIX, QTWO, RBCN, RENT, RIG, ROVI, RPTP, RRMS, RSYS, RXN, SAPE, SF, SFM, SLXP, SPPI, SSTK, SWKS, TCRD, TKMR, TRMR, TRNX, TUMI, UBNT, UEPS, UNXL, VOLC, VRNS, VVC, WAGE, WIFI, XOMA, XOXO, YUME, ZGNX, ZNGA
Nov. 3, 2014, 2:37 PM
Sep. 30, 2014, 7:46 AM
- A 365-patient Phase 2 clinical trial evaluating the safety and efficacy of Acasti Pharmaceuticals' (NASDAQ:ACST) CaPre (highy purified omega-3 concentrate from krill oil) for the treatment of patients with hypertriglyceridemia met all primary and secondary endpoints.
- The trial was a randomized, placebo-controlled, double-blind, dose-ranging study designed to assess CaPre's safety and efficacy in reducing triglyceride levels in patients with mild-to-severe hypertriglyceridemia taking daily doses of 1 gram or 2 grams of CaPre or placebo over a 12-week period. Approximately 90% of the patients had baseline triglycerides between 200 and 499 mg/dL. The remainder had triglycerides between 500 and 877 mg/dL.
- The study met its primary endpoint of a statistically significant mean placebo-adjusted decrease in triglycerides from baseline to week 12. The CaPre 1 gram cohort showed a reduction of 36.4% and the CaPre 2 gram showed a reduction of 38.6%.
- There was a statistically significant decrease of 5.3% from baseline in non-HDL-C compared to placebo. There was a slight increase in HDL-C for both the 1 gram and 2 gram doses.
- Acasti expects complete results from the trial by the end of 2014. It plans to move forward with a Phase 3 trial and a regulatory submission for CaPre as a treatment for severe hypertriglyceridemia.
- Related tickers: (NASDAQ:NEPT) (NASDAQ:AMRN)
Sep. 12, 2014, 12:45 PM
Sep. 12, 2014, 9:21 AM
Sep. 12, 2014, 9:12 AM
Aug. 7, 2014, 4:40 PM
Aug. 7, 2014, 4:08 PM
Aug. 6, 2014, 5:35 PM
- AGO, AHT, AIRM, AL, ALIM, ALJ, ALNY, AMRN, AMRS, ANAC, ANET, ASYS, ATLS, AUQ, BCEI, BCOR, BIOL, BNFT, BNNY, BOFI, BPZ, CARA, CBS, CENT, CFN, CLNE, CLVS, CPST, CSC, CUBE, CVT, DAR, DIOD, DMD, DV, EAC, EBS, ECPG, ED, EGOV, ELX, ENOC, FF, FI, FRT, FWM, FXCM, GHDX, GST, GXP, HGR, HTGC, IRG, KTOS, LGF, MASI, MDVN, MED, MELI, MNST, NES, NFG, NOG, NVDA, NWSA, OLED, OPLK, PFMT, PODD, PRO, PSIX, QTWO, RATE, RBCN, RENT, RPTP, RRMS, SCTY, SEM, SFM, SHOR, SLXP, SPPI, SSTK, TEAR, TRNX, TRUE, TUMI, UBNT, UNXL, VOLC, VVUS, WIFI, XOMA, ZNGA,
Jul. 31, 2014, 9:11 AM| 4 Comments
AMRN vs. ETF Alternatives
Other News & PR